May 13, 2022 – Eli Lilly’s MounjaroTM (tirzepatide) has received FDA approval for use alongside diet and exercise to improve blood sugar control in adults who have type 2 diabetes.
May 12, 2022 – Sandoz has launched the first fully substitutable generic for Genentech’s Esbriet® (pirfenidone) tablets. Esbriet is also available in capsule form
May 12, 2022 – Radicava ORS® (edaravone – Mitsubishi Tanabe Pharma America), has received FDA approval to treat amyotrophic lateral sclerosis (ALS) in adults.
May 4, 2022 – The U.S. FDA has granted regular approval to Enhertu® (fam-trastuzumab deruxtecan-nxki)
as a treatment for unresectable or metastatic HER2-positive
May 4, 2022 – Phathom Pharmaceuticals’ VoqueznaTM Triple Pack (vonoprazan/amoxicillin/clarithromycin) and VoqueznaTM Double Pack (vonoprazan/amoxicillin) have been approved
May 2, 2022 – Supernus Pharmaceuticals’ Qelbree® (viloxazine extended-release capsules) has received an expanded indication to treat attention deficit hyperactivity